All Posts

MedTech Reimbursement strategy is not optional at Series A, but its weight varies significantly by technology type. You don't need a solved reimbursement problem. You need to demonstrate you understand the path, the risks, and the capital required to get there. Founders who treat reimbursement as a post-approval problem consistently lose deals to those who've built it into product, clinical, and commercial strategy from day one.

Commercialization is typically the most capital-intensive phase for a medical device company. The product is technically de-risked after FDA clearance, but the business risk increases. The objective of the commercialization financial strategy is to secure sufficient capital to support manufacturing scale-up, sales organization development, and early adoption without facing a liquidity crisis during the slow initial revenue ramp.

A company developing a minimally invasive device typically experiences value creation in discrete scientific and regulatory steps. Investors finance the company in stages because risk declines as the device moves from concept to clinical validation. The CFO’s role is to align capital deployment with these inflection points so that the company reaches each MedTech financial milestone with sufficient resources but without carrying excess burn before value is created.